Teplizumab + Placebo
Phase 2/3Completed 0 watching 0 views this week๐ Rising
65
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitus
Conditions
Type 1 Diabetes Mellitus
Trial Timeline
Oct 1, 2006 โ Aug 1, 2011
NCT ID
NCT00385697About Teplizumab + Placebo
Teplizumab + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT00385697. Target conditions include Type 1 Diabetes Mellitus.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00385697 | Phase 2/3 | Completed |
Competing Products
20 competing products in Type 1 Diabetes Mellitus